Seoul, Sept. 29, 2022 (GLOBE NEWSWIRE) -- Global demand for hemostasis and tissue sealing agents is expected to surge ahead at a CAGR of 8.5% from 2022 to 2027 and reach a market valuation of US$ 7.6 billion by 2027, says Fact.MR, market research and competitive intelligence provider.
The success of a patient's recovery after a urologic surgery heavily depends on blood loss management. During surgical repair, hemostatic agents and tissue sealants are widely employed in reconstruction to stop excessive blood loss. Thrombin sealants, bovine serum/albumin/glutaraldehyde, fibrin glue, and gelatin matrix are a few of the solutions that are available, with each of these agents having a unique mechanism, price, and use.
The possibilities of developing thrombosis or allergic reactions, as well as hepatitis or bovine spongiform encephalitis, are all the possible complications. Numerous new hemostatic medications are being created and approved. The surgeon need to weigh the advantages and disadvantages of using these agents in comparison to standard treatment on a case-by-case basis.
Get a Sample PDF of This Research Report with a Detailed Table of Content:
https://www.factmr.com/connectus/sample?flag=S&rep_id=7705
Globally, rising accident and trauma cases will fuel market expansion for hemostasis products. Demand for hemostasis and tissue sealing agents is expected to rise as more operations are conducted around the world because these products are essential for wound healing. Heart disease, stroke, cancer, and injuries are the main reasons for surgery. Also, any surgical procedure has a chance of experiencing serious problems that could lead to excessive bleeding, which would increase the need for hemostasis products.
Other prominent factors that would drive the market for hemostasis and tissue sealing agents over the coming years are high-level technological developments, robust economies, and a swarming pool of patients with a variety of blood illnesses.
Key Takeaways from Market Study
- The global market for hemostasis and tissue sealing agents is currently valued at US$ 5 billion.
- Global sales of topical hemostats are predicted to rise at an impressive CAGR of 9.5% from 2022 to 2027.
- The China market is expected to expand at a giant CAGR of 13% and reach US$ 1.6 billion by 2027.
- Due to their effectiveness in reducing bleeding during surgery, tissue sealants and tissue adhesive solutions are seeing an increase in sales.
- Hemostasis and tissue sealing agents are simple to apply, very effective, and highly affordable.
Increasing Incidence of Chronic Disorders Needing Surgery
Patients who are elderly need immediate attention and are more likely to get wounds and injuries that take a long time to recover. The market is predicted to develop as a result of an increase in the number of common injuries and wounds due to a demographic trend toward an active lifestyle.
Most chronic conditions ultimately necessitate surgical procedures, which subsequently promote market growth. A few chronic illnesses that call for these goods are hernia fixation, diabetes, spinal injuries, urological disorders, ocular injuries and replacements, and burns.
These solutions were chosen over alternative wound closure techniques, which resulted in an expansion of their applications, particularly in endoscopic treatments. Endoscopic hemostatic therapy is effective for the treatment of peptic ulcers.
The market for hemostasis and tissue sealing products serves patients with everything from minor wounds to burns and neurosurgical treatment.
Speak to Analyst:
https://www.factmr.com/connectus/sample?flag=AE&rep_id=7705
Winning Strategy
Partnerships with hospitals and care facilities, R&D in formulation development, inclusion of bacteriostatic qualities, and aggressive marketing strategies for natural adhesives, particularly fibrin sealants, are some of the strategic tactics that market players are anticipated to adopt.
Additionally, businesses are engaging in mergers and acquisitions aimed at enhancing their regional presence and assuring sustainability.
Recently, in July 2021:-
- Baxter International Inc. stated that its Baxter Healthcare Corporation subsidiary has finished buying some assets connected to the PerClot Polysaccharide Hemostatic System from CryoLife, Inc. The acquisition supports Baxter's acquisition strategy, which entails purchasing goods and innovations that enhance and add to the company's premier portfolio throughout the hospital, particularly in the operating/surgical theatre. With sales in more than 35 nations, PerClot has a global commercial footprint.
Competitive Landscape
The leading companies in the global hemostasis and tissue sealing agents market are involved in product launches, manufacturing technologically cutting-edge solutions, acquisitions, and joint ventures with other businesses.
These tactics are probably going to help the market for tissue sealing and hemostasis agents increase around the globe.
- The Terumo Corporation introduced AQUABRID, a novel surgical sealant product, to the EMEA market on January 26, 2020. Using this product during aortic surgery helps to halt bleeding.
- Johnson & Johnson (Ethicon, Inc.) (U.S) dominates the market for tissue sealants and tissue glue. The company enjoys a strong regional presence and a well-known brand. It also offers a wide variety of surgical sealants and adhesives, including some of the most recognizable brands.
Quick Buy: Hemostasis And Tissue Sealing Agents Market Research Report
https://www.factmr.com/checkout/7705
Segmentation of Hemostasis and Tissue Sealing Agents Industry Research
- By Product :
- Topical Hemostats
- Adhesive & Tissue Sealants
- By End User :
- Hospitals
- Ambulatory Surgery Centers
- Home Care Settings
- Others
- By Region :
- North America
- Latin America
- Europe
- East Asia
- South Asia & Oceania
- ME
More Valuable Insights on Offer
Fact.MR, in its new offering, presents an unbiased analysis of the global hemostasis and tissue sealing agents market, presenting historical demand data (2017-2021) and forecast statistics for the period of 2022-2027.
The study divulges essential insights on the market on the basis of product (topical hemostats, adhesive & tissue sealants) and end user (hospitals, ambulatory surgery centers, home care settings, others), across five major regions of the world (North America, Europe, Asia Pacific, Latin America, and MEA).
Check out more related studies published by Fact.MR Research:
Wound Healing Supplement Market: According to the latest research by Fact.MR the Wound healing Market is set to witness steady growth during 2021-2031, globally. The advanced wound healing market is expected to reach (USD) 16.5 billion by 2027 from USD 10.3 billion in 2020, at a CAGR of 9%.
Advanced Wound Care Market: The advance wound care market is poised to leverage at a CAGR of ~4% between 2020 and 2030. Rising incidence of type-1 diabetes has augmented treatment for diabetic ulcers. Presently, more than 4.5 million patients with diabetic pressure ulcers require treatment. Moreover, a significant number of patients suffer from venous ulcers. North America and Europe jointly dominate the global advanced wound care market, capturing more than 70% of the market.
Hemostasis Valves Market: According to the latest research by Fact.MR., the Hemostasis Valves Market is set to witness steady growth during 2021-2031. The increasing advancement in the hemostasis valves industry will offer lucrative opportunities and an increasing number of interventional procedures is propelling the market growth.
Soft Tissue Markers Market: The increasing application of diagnostic imaging is expected to drive the growth of the market. The increasing application of diagnostic imaging is expected to drive the growth of the market. Rapid turnaround time and lower cost of the procedure as compared to conventional methods are factors also expected to fuel the growth of the soft tissue markers market.
Tissue Processor Equipment Market: Expanding at a CAGR of 4.8%, the global tissue processor equipment market is projected to increase from a valuation of US$ 426.30 million in 2022 to US$ 681 million by 2032-end. The prevalence of health problems is rising quickly across the world. The development of novel viruses, airborne infections, more advanced strains of existing viruses, and the emergence of mutants, have made it necessary to create a variety of devices that can accurately inform patients about their illnesses.
About Us:
Market research and consulting agency with a difference! That’s why 80% of Fortune 1,000 companies trust us for making their most critical decisions. While our experienced consultants employ the latest technologies to extract hard-to-find insights, we believe our USP is the trust clients have on our expertise. Spanning a wide range – from automotive & industry 4.0 to healthcare & retail, our coverage is expansive, but we ensure even the most niche categories are analyzed. Our sales offices in United States and Dublin, Ireland. Headquarter based in Dubai, UAE. Reach out to us with your goals, and we’ll be an able research partner.
Contact:
Mahendra Singh
US Sales Office:
11140 Rockville Pike
Suite 400
Rockville, MD 20852
Email: sales@factmr.com
